Certified by Founder
Lodge
DalCor Pharmaceuticals
start up
Canada
- Montreal, Québec
- 22/09/2023
- Series D
- $80,000,000
DalCor Pharmaceuticals: DalCor Pharmaceuticals is pioneering precision medicine for patients with cardiovascular disease. By combining genetic and clinical insights, the company’s development program, dalcetrapib, is intended to reduce fatal and non-fatal myocardial infarction (MI) following a recent acute coronary syndrome and deliver superior cardiovascular outcome in a specific genetic subset of patients.
- Industry Biotechnology Research
- Website https://dalcorpharma.com/
- LinkedIn https://www.linkedin.com/company/dalcor-pharmaceuticals/about/
Maritime Fusion | $4,500,000 | (Nov 25, 2025)
Opti | $20,000,000 | (Nov 25, 2025)
Cordance Medical | $8,000,000 | (Nov 25, 2025)
Redrob | $10,000,000 | (Nov 25, 2025)
Pibit.AI | $7,000,000 | (Nov 25, 2025)
Votre | $3,750,000 | (Nov 25, 2025)
Tidalwave | $22,000,000 | (Nov 25, 2025)
Relixir | $2,000,000 | (Nov 25, 2025)
Interface | $3,500,000 | (Nov 25, 2025)
Model ML | $75,000,000 | (Nov 25, 2025)
Mirantus Health | $6,338,062 | (Nov 25, 2025)